Page last updated: 2024-12-10
coelichelin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
coelichelin: a tetrapeptide siderophore from Streptomyces coelicolor produced by nonribosomal peptide biosynthesis; has been sequenced [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
coelichelin : A tetrapeptide hydroxamate siderophore that is isolated from Streptomyces coelicolor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3247071 |
| CHEBI ID | 80049 |
| MeSH ID | M0369110 |
Synonyms (6)
| Synonym |
|---|
| (2s)-2-[[(2r)-2-amino-5-[formyl(hydroxy)amino]pentanoyl]amino]-5-[[(2r,3r)-2-[[(2r)-2-amino-5-[formyl(hydroxy)amino]pentanoyl]amino]-3-hydroxybutanoyl]-hydroxyamino]pentanoic acid |
| 2-[2-amino-5-(formyl-hydroxy-amino)-pentanoylamino]-5-({2-[2-amino-5-(formyl-hydroxy-amino)-pentanoylamino]-3-hydroxy-butyryl}-hydroxy-amino)-pentanoic acid |
| coelichelin |
| CHEBI:80049 |
| n(2)-(n(5)-formyl-n(5)-hydroxy-d-ornithyl)-n(5)-(n(5)-formyl-n(5)-hydroxy-d-ornithyl-d-allothreonyl)-n(5)-hydroxy-l-ornithine |
| Q27149200 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, its bioavailability is reduced in aerobic environments, such as soil." | ( Pseudomonas fluorescens pirates both ferrioxamine and ferricoelichelin siderophores from Streptomyces ambofaciens. Aigle, B; Deveau, A; Frey-Klett, P; Galet, J; Hôtel, L; Leblond, P, 2015) | 0.66 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| siderophore | Any of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| tetrapeptide | Any molecule that contains four amino-acid residues connected by peptide linkages. |
| hydroxamic acid | A compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides. |
| formamides | Amides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.98
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.98) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||